Loading people...
Harry Glorikian is a General Partner at New Ventures Funds, a distinguished author, and a recognized expert in health technology and life sciences. He is known for his strategic insights into healthcare innovation and commercialization.
Harry Glorikian primarily invests in transformative companies within the health technology and life sciences sectors. His focus areas include digital health, precision medicine, diagnostics, biotechnology, and health data analytics.
Harry Glorikian works as a General Partner at New Ventures Funds, a venture capital firm dedicated to investing in groundbreaking innovations.
Harry Glorikian is a General Partner at Scientia Ventures based in New York, USA. He brings over 30 years of experience to his investment role, previously serving as Entrepreneur in Residence at GE Ventures, where his work led to the founding of Evidation Health and DrawBridge Health. Earlier in his career, he co-founded and served as Managing Director of Scientia Advisors, a healthcare consulting firm acquired by Precision for Medicine in 2012. Glorikian holds four US patents in telecommunications, serves as a Research Affiliate at the MIT Media Lab, and has authored three books on healthcare technology. At Scientia Ventures, he helped close the $90 million New Ventures III fund in 2019 and holds board positions at companies including StageZero Life Sciences. His current focus centers on the intersection of artificial intelligence, biological data, and digital systems.
Harry Glorikian is a distinguished General Partner at New Ventures Funds, bringing a wealth of experience and strategic vision to the firm's investment activities. In this pivotal role, he is instrumental in shaping the fund's portfolio, identifying companies poised for significant disruption and growth within the health technology and life sciences sectors. His leadership ensures that New Ventures Funds remains at the forefront of investing in the next generation of healthcare innovation.
Glorikian's investment thesis centers on transformative technologies and solutions that address critical unmet needs in healthcare. He actively seeks out companies specializing in digital health, precision medicine, diagnostics, biotechnology, and health data analytics. His keen understanding of market dynamics and technological advancements allows him to pinpoint ventures with strong commercialization potential and the capacity to redefine patient care and outcomes. He is particularly interested in innovations that bridge the gap between scientific discovery and practical application, driving efficiency and effectiveness across the healthcare continuum.
Prior to his role at New Ventures Funds, Harry Glorikian built an impressive career marked by deep engagement in the life sciences and health technology industries. He is widely recognized as a strategic advisor, author, and thought leader. His background includes significant experience in corporate development, strategic planning, and commercialization for both startups and established enterprises. Glorikian has a proven track record of guiding companies through complex market landscapes, helping them to develop robust strategies for growth and market penetration. He is also the author of acclaimed books such as "MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Economy" and "The Future You: How Artificial Intelligence Can Help You Get Healthier, Richer, and Smarter," underscoring his expertise and forward-thinking perspective on the future of health and technology. This diverse experience provides him with a unique vantage point for evaluating investment opportunities and mentoring portfolio companies.
While specific individual investments are often confidential or not publicly detailed, Harry Glorikian's focus at New Ventures Funds is on building a robust portfolio of companies that exemplify innovation and market leadership. He seeks out ventures with strong intellectual property, scalable business models, and visionary leadership teams. His involvement extends beyond capital injection, offering strategic guidance, market access, and operational expertise to help portfolio companies achieve their milestones and accelerate their path to success. The fund's strategy, guided by Glorikian, aims to back companies that are not just financially promising but also have the potential for profound societal impact in healthcare.
